Home LiteratureArticle Details
PMID: 7729895 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

Infection and immunity ·Vol. 63 ·No. 5 ·1995-05-00 ·Pages 1855-62

von Specht BU, Knapp B, Muth G, Bröker M, Hungerer KD, Diehl KD, Massarrat K, Seemann A, Domdey H

Abstract

Recombinant outer membrane proteins (Oprs) of Pseudomonas aeruginosa were expressed in Escherichia coli as glutathione S-transferase (GST)-linked fusion proteins. GST-linked Oprs F and I (GST-OprF190-350 [GST linked to OprF spanning amino acids 190 to 350] and GST-OprI21-83, respectively) and recombinant hybrid Oprs (GST-OprF190-342-OprI21-83 and GST-OprI21-83-OprF190-350) were isolated and tested for their efficacy as vaccines in immunodeficient mice. GST-OprF-OprI protected the mice against a 975-fold 50% lethal dose of P. aeruginosa. Expression of GST-unfused OprF-OprI failed in E. coli, although this hybrid protein has been expressed without a fusion part in Saccharomyces cerevisiae and used for immunizing rabbits. The immune rabbit sera protected severe combined deficient (SCID) mice against a 1,000-fold 50% lethal dose of P. aeruginosa. Evidence is provided to show that the most C-terminal part of OprF (i.e., amino acids 332 to 350) carries an important protective epitope. Opr-based hybrid proteins may have implications for a clinical vaccine against P. aeruginosa.

Related Genes
oprF oprI
MeSH Terms
Animals Antibodies, Bacterial/therapeutic use Antibodies, Monoclonal/therapeutic use Bacterial Proteins/genetics,immunology,therapeutic use Base Sequence Epitope Mapping Escherichia coli/genetics Female Immunosuppression Therapy Immunotherapy Immunotherapy, Active Immunotherapy, Adoptive Lipoproteins/genetics,immunology,therapeutic use Mice Mice, Inbred BALB C Mice, SCID Molecular Sequence Data Porins/genetics,immunology,therapeutic use Pseudomonas Infections/mortality,prevention & control Recombinant Fusion Proteins/therapeutic use Saccharomyces cerevisiae/genetics Survival Analysis
Chemicals
Antibodies, Bacterial Antibodies, Monoclonal Bacterial Proteins Lipoproteins Porins Recombinant Fusion Proteins outer membrane lipoprotein I, Bacteria
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
von Specht B U
Chirurgische Universitätsklinik, Chirurgische Forschung, Freiburg, Germany.
Knapp B
Muth G
Bröker M
Hungerer K D
Diehl K D
Massarrat K
Seemann A
Domdey H
References (35)
35 references, click to expand
  1. Controlled trials of a polyvalent pseudomonas vaccine in burns.
    Lancet. 1979 Nov 10;2(8150):977-82 PMID: 91774
  2. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin.
    Vaccine. 1994 Oct;12(13):1215-21 PMID: 7839727
  3. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.
    Infect Immun. 1983 Mar;39(3):1067-71 PMID: 6404816
  4. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.
    Infect Immun. 1984 Apr;44(1):49-54 PMID: 6323316
  5. Opportunistic infections in severely burned patients.
    Am J Med. 1984 Mar 30;76(3A):146-54 PMID: 6369976
  6. Characterization of two surface-localized antigenic sites on porin protein F of Pseudomonas aeruginosa.
    Can J Microbiol. 1985 Apr;31(4):381-6 PMID: 2408719
  7. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center.
    Eur J Clin Microbiol. 1985 Apr;4(2):219-23 PMID: 3924612
  8. Plaque antibody selection: rapid immunological analysis of a large number of recombinant phage clones positive to sera raised against Plasmodium falciparum antigens.
    J Immunol Methods. 1986 May 22;89(2):213-9 PMID: 3517177
  9. Intrinsic antibiotic resistance of Pseudomonas aeruginosa.
    J Antimicrob Chemother. 1986 Dec;18(6):653-6 PMID: 3102446
  10. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    J Infect Dis. 1987 Jun;155(6):1282-91 PMID: 3033095
  11. A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae.
    EMBO J. 1987 Jan;6(1):229-34 PMID: 3034576
  12. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection.
    Infection. 1987;15(5):408-12 PMID: 3121520
  13. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene.
    J Bacteriol. 1988 Jan;170(1):155-62 PMID: 2447060
  14. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    J Lab Clin Med. 1988 Jun;111(6):701-7 PMID: 3131471
  15. A histidin alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection.
    Behring Inst Mitt. 1988 Apr;(82):349-59 PMID: 3044343
  16. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.
    Gene. 1988 Jul 15;67(1):31-40 PMID: 3047011
  17. Induction of protective immune response by vaccination against Pseudomonas pneumonia of mink.
    Zentralbl Veterinarmed B. 1988 May;35(4):256-63 PMID: 3138862
  18. Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli.
    Gene. 1988 Sep 30;69(2):301-15 PMID: 3069586
  19. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Microb Pathog. 1989 Jan;6(1):75-80 PMID: 2733597
  20. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.
    Gene. 1989 Apr 15;77(1):61-8 PMID: 2744488
  21. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.
    J Bacteriol. 1989 Aug;171(8):4130-7 PMID: 2502533
  22. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital.
    J Infect Dis. 1989 Dec;160(6):1030-6 PMID: 2511252
  23. Pseudomonas bacteremia in a community teaching hospital, 1980-1984.
    Rev Infect Dis. 1989 Nov-Dec;11(6):846-52 PMID: 2602775
  24. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
    Infect Immun. 1990 Jul;58(7):2241-4 PMID: 2114360
  25. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem.
    Surgery. 1991 Jan;109(1):62-8 PMID: 1984637
  26. Responses of T cells from sensitized donors to recombinant and synthetic peptides corresponding to sequences of the Plasmodium falciparum SERP antigen.
    Immunol Lett. 1990 Aug;25(1-3):149-53 PMID: 1704344
  27. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
    Infect Immun. 1991 Apr;59(4):1251-4 PMID: 1706316
  28. Expression of the human blood coagulation protein factor XIIIa in Saccharomyces cerevisiae: dependence of the expression levels from host-vector systems and medium conditions.
    Appl Microbiol Biotechnol. 1991 Mar;34(6):756-64 PMID: 1369455
  29. Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice.
    Vaccine. 1991 Sep;9(9):675-81 PMID: 1950099
  30. Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa.
    Infect Immun. 1992 Sep;60(9):3497-503 PMID: 1379985
  31. Molecular and cellular basis of immune protection of mucosal surfaces.
    Physiol Rev. 1992 Oct;72(4):853-79 PMID: 1438580
  32. Naked DNA points way to vaccines.
    Science. 1993 Mar 19;259(5102):1691-2 PMID: 8456293
  33. Expression of hepatitis B virus core gene products with specific immunoreactivity for e antigen (HBeAg) in Saccharomyces cerevisiae.
    J Biotechnol. 1993 Jun;29(3):243-55 PMID: 7763899
  34. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha.
    Infect Immun. 1994 Dec;62(12):5335-43 PMID: 7960112
  35. Outer membrane proteins of Pseudomonas aeruginosa serotype strains.
    J Infect Dis. 1982 Dec;146(6):770-9 PMID: 6183370
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
DOI
10.1128/iai.63.5.1855-1862.1995
Published
1995-05-00
Pages
1855-62
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC173235
Subset
IM
External Links
PubMed source DOI: 10.1128/iai.63.5.1855-1862.1995 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2